Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know.

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price objective raised by Scotiabank from $78.00 to $80.00 in a research report sent to investors on Thursday,Benzinga reports. They ...

EXCLUSIVE: The parents of two siblings with a life-limiting condition are waiting in agony to find out if health chiefs will ...

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for the bleeding condition.

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

Full Year 2024 Results Key Financial Results Revenue: US$2.85b (up 18% from ...

The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with ...